A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

Conditions:   Growth Hormone Disorder;   Adult Growth Hormone Deficiency
Interventions:   Drug: somapacitan;   Drug: Norditropin
Sponsor:   Novo Nordisk A/S
Recruiting - verified March 2017

http://ift.tt/2n3wmxY